Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiology0372-93112686-7613Central Research Institute for Epidemiology37310.36233/0372-9311-2019-3-91-99Interferon status as a method of determination of nonspecific biomarkers of human immunopathologyErshovF. I.<p>Moscow</p>fake@neicon.ruOspelnikovaT. P.<p>Moscow</p>fake@neicon.ruNarovlyanskyA. N.<p>Moscow</p>fake@neicon.ruGamaleya National Research Center of Epidemiology and MicrobiologyMechnikov Research Institute of Vaccines and Sera2208201996391992208201922082019Copyright © 2019, Ershov F.I., Ospelnikova T.P., Narovlyansky A.N.2019<p class="MsoNormal"><span lang="EN-US">For more than 60 years, the study of interferons (IFN) system has continued, as a complex network system. IFNs of 3 types are discovered: I (</span>α<span lang="EN-US">/</span>β<span lang="EN-US">), II (</span><span lang="EN-US">ƴ</span><span lang="EN-US">), III (</span><span lang="EN-US">λ</span><span lang="EN-US">), their interrelations, mechanisms of action, functional diversity are investigated. The practical way out of the study of the functional capacity of human peripheral blood leukocytes to produce IFN was the method of determining the interferon status, which allows to judge the immunoreactivity of the organism, to detect the sensitivity of blood cells to immunoac-tive drugs and makes it possible to determine the tactics of treatment in different forms of pathology and predict the outcome of the disease. An improved method of IFN status has been proposed and scientifically justified, the indicators of which can now be considered as characteristics of nonspecific biomarkers of human immunopathology.</span></p>interferons I (α/β)II (ƴ)III (λ) typesinterferon statusimproved methodologynonspecific biomarkershuman immunopathologyинтерфероны I (α/β)II (ƴ)III (λ) типовинтерфероновый статусусовершенствованная методиканеспецифические биомаркерыиммунопатологии человека[1. Бойко А.Н., Бойко О.В., Гусев Е.И. Выбор оптимального препарата для патогенетического лечения рассеянного склероза: современное состояние проблемы (обзор литературы). Журнал неврологии и психиатрии им.С.С.Корсакова. 2014; вып.2, 114(2):77-91.][2. Григорян С.С., Майоров И.А., Иванова А.М., Ершов Ф.И. Оценка интерферонового статуса по пробам цельной крови. Вопросы вирусологии. 1988; 4:433-436.][3. Григорян С.С., Оспельникова ТП., Ершов Ф.И. Определение индивидуальной чувствительности людей к индукторам интерферона и другим препаратам (по воздействию на интерфероновый статус). Методические рекомендации. М., НИИЭМ им.Н.Ф.Гамалеи, 2000.][4. Государственная Фармакопея РФ, XIII издание. М., 2015. ОФС.1.7.2.0002.15 Биологические методы испытания препаратов интерферона с использованием культур клеток.][5. Ершов Ф.И. Лекарственные средства для лечения вирусных инфекций. Рациональная антимикробная химиотерапия. М., 2003.][6. Ершов Ф.И., Готовцева Е.П., Носик Н.Н. Интерфероновый статус в норме. Иммунология. 1986, 3:52-54.][7. Ершов Ф.И., Готовцева Е.П., Лаврухина Л.А. Интерфероновый статус при различных заболеваниях. Вопросы вирусологии. 1990, 6:444-448.][8. Ершов Ф.И. Система интерферона в норме и при патологии. М., Медицина, 1996.][9. Ершов Ф.И., Наровлянский А.Н. Интерфероны и индукторы интерферонов. В кн.: Иммунотерапия. Под ред. РМ.Хаитова, РИ.Атауллаханова, А.Е.Шульженко. М., ГЕОТАР-Медиа, 2018:123-147.][10. Интерфероновый статус, препараты интерферона в лечении и профилактике инфекционных заболеваний и реабилитация больных. Под ред. С.С.Афанасьева, Г.Г.Онищенко, В.А.Алешкина, М.С.Афанасьева М., Триада-Х, 2005.][11. Оспельникова Т.П., Носейкина Е.М., Гайдерова Л.А., Ершов Ф.И. Терапевтический потенциал препаратов альфа интерферонов при социально-значимых заболеваниях человека вирусной этиологии. Журн. микробиол. 2016, 5:109-121.][12. Оспельникова Т.П., Григорян С.С., Ершов Ф.И. Новый подход к отбору иммуноактивных препаратов для лечения. Медицинская иммунология. 2001, 3(2):332-333.][13. Оспельникова Т.П., Колодяжная Л.В., Табаков В.Ю., Ершов Ф.И. Способ определения продукции интерферонов как параметров врожденного иммунитета. Патент на изобретение РФ №2657808 от 10.07.2017, опубликован: 15.06.2018.][14. Соловьев В.Д., Бектемиров ТА. Интерфероны в теории и практике медицины. М., Медицина, 1979.][15. Bugge M., Bergstrom B., Eide O.K. et al. Surface Toll-Like Receptor 3 Expression in Metastatic Intestinal Epithelial Cells Induces Inflammatory Cytokine Production and Promotes Invasiveness. J. Biol. Chem. 2017. pii: jbc.M117.784090. doi: 10.1074/jbc.M117.784090.][16. Campbell J.B., Grunberger T, Kochman M.A., White S.L. A microplaque reduction assay for human and mouse interferon. Can. J. Microbiol. 1975; 21(8):1247-1253.][17. Cua D.J., Sherlock J., Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003, 421(6924):744-748.][18. Dahl H. et al. Preventive effect of a nonviral interferon inducer, a bacterial vaccine, on experimental influenza in mice. Acta Pathol. Microbiol. Scand. B. Microbiol. Immunol. 1972, 80(3):467-474.][19. Doldi K., Leroux M., Augustin R. et al. Proliferation and interferon production in whole blood samples and isolated lymphocyte preparations. J. Interferon Res. 1985, 5(1):55-64.][20. Ferreira P.C., Peixoto M.L., Silva M.A., Golgher R.R. Assay of human interferon in Vero cells by several methods. J. Clin. Microbiol.1979, 9(4):471-475.][21. Flisiak R., Shiffman M., Arenas J. et al. Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C. PLoS One. 2016 Oct 17; 11(10):e0164563. doi: 10.1371/journal.pone.0164563.eCollection 2016.][22. Forster S. Interferon signatures in immune disorders and disease. Immunol. Cell. Biol. 2012, 90(5): 520-527. doi: 10.1038/icb.2012.12.][23. Hamming O.J., Gad H.H., Paludan S., Hartmann R. Lambda Interferons: New Cytokines with Old Functions. Pharmaceuticals. 2010, 3: 795-809; doi:10.3390/ph3040795.][24. Hermann M., Bogunovic D. ISG15: in sickness and in health. Trends Immunol (2017) 38:79-93.10.1016/j.it.2016.11.001.][25. Hillyer P., Mane V.P., Schramm L.M. et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol. Cell. Biol. 2012 Jan 17. doi: 10.1038/icb.2011.109.][26. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci. (1957) 147:258-67.10.1098/rspb.1957.0048.][27. Kiefer K., Oropallo M.A., Cancro M.P., Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol. Cell. Biol. 2012, 90(5):498-504. doi: 10.1038/icb.2012.10.][28. Kirchner H., Kleinicke C., Digel W. A whole-blood technique for testing production ofhuman interferon by leukocytes. J. Immunol. Methods. 1982, 48(2):213-219.][29. Kopitar-Jerala N. The Role of Interferons in Inflammation and Inflammasome Activation. Front Immunol. 2017, 8: 873. doi: 10.3389/fimmu.2017.00873.][30. Kotenko S.V., Gallagher G., Baurin V.V et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4(1):69-77.][31. Lee S., Baidridge M.T. Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. Front Immunol. 2017, 8:749. doi: 10.3389/fimmu.2017.00749.eCollection 2017.][32. MacMicking J.D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. (2012) 12:367-82.10.1038/nri3210.][33. Mangan N.E., Fung K.Y Type I interferons in regulation of mucosal immunity. Immunol Cell Biol. 2012, 90(5): 510-519. doi: 10.1038/icb.2012.13.][34. McNab F., Mayer-Barber K., Sher A. et al. Type I interferons in infectious disease. Nat. Rev. Immunol. (2015) 15:87-103.10.1038/nri3787.][35. Meunier E., Broz P. Interferon-inducible GTPases in cell autonomous and innate immunity. Cell. Microbiol. (2016) 18:168-80.10.1111/cmi.12546.][36. Musella M., Manic G., De Maria R. et al. Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. Oncoimmunology. 2017; 6(5):e1314424. doi: 10.1080/2162402X.2017.1314424.eCollection 2017.][37. Ospelnikova T.P., Morozova O.V., Isaeva E.I. et al. Respiratory Viruses and Proinflammatory Cytokines Imbalance in Adults and Children with Bronchial Asthma. Journal of Infectious Diseases. Preventive Medicine, an open access journal. ISSN: 2329-8731. 2016; Volume 4, Issue 2, 1000138. DOI: 10.4172/2329-8731.1000138.][38. Pilla-Moffett D., Barber M.F., Taylor G.A., Coers J. Interferon-inducible GTPases in host resistance, inflammation and disease. J. Mol. Biol. (2016) 428:3495-513. 10.1016/j.jmb.2016.04.032.][39. Pitha J., Adams R., Pitha P.M. Viral probe into the events of cellular (in vitro) aging. J. Cell Physiol. 1974; 83(2):211-8.][40. Rauch I., Mdller M., Decker T The regulation of inflammation by interferons and their STATs. JAKSTAT (2013) 2:e23820.10.4161/jkst.23820.][41. Razaghi A., Villacres C., Jung V. et al. Improved therapeutic efficacy of mammalian expressed-rec ombinant interferon gamma against ovarian cancer cells. Exp. Cell. Res. 2017 Aug 10. pii: S0014-4827(17)30425-1. doi: 10.1016/j.yexcr.2017.08.014.][42. Richmond J.Y, Polatnick J., Knudsen R.C. Microassay for interferon, using [3H]uridine, microculture plates, and a multiple automated sample harvester. Appl. Environ. Microbiol. 1980, 39(4): 823-827.][43. Rubinstein S., Familletti P.C., Pestka S. Convenient assay for interferons. J. Virol. 1981, 37(2):755-758.][44. Sidwell R.W, Huffman J.H. Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl. Microbiol. 1971; 22(5):797-801.][45. Sui H., Zhou M., Imamichi H. et al. STING is an essential mediator of the Ku70-mediated production of IFN-X1 in response to exogenous DNA. Sci Signal. 2017; 10(488). Pii: eaah5054. doi: 10.1126/scisignal.aah5054.][46. Tilles J.G., Finland M. Microassay for Human and Chick Cell Interferons. Applied Microbiology. 1968; 16 (11):1706-1707.][47. Trinchieri G. Type I interferon: friend or foe? J. Exp. Med. (2010) 207:2053—63.10.1084/jem.20101664.][48. Ueno H., Klechevsky E., Morita R. et al. Dendritic cell subsets in health and disease. Immunol. Rev. 2007 Oct;219:118-142.][49. Wang S., Sun X., Yi C. et al. Negatively Regulates Type I Interferon Signaling Pathway by Competition Binding IRF3 with CBP/p300. Front. Cell. Infect. Microbiol. 2017, 7:195. doi: 10.3389/fcimb.2017.00195.eCollection 2017.][50. Yoshizumi T, Imamura H., Taku T et al. RLR-mediated antiviral innate immunity reguires oxidative phosphorylation activity. Sci. Rep. 2017, 7(1):5379. doi: 10.1038/s41598-017-05808-w.][51. Zha Z., Bucher F., Nejatfard A., Zheng T et al. Interferon-y is a master checkpoint regulator of cytokine-induced differentiation. Proc. Natl. Acad. Sci. USA. 2017. pii: 201706915. doi: 10.1073/pnas.1706915114.]